You are currently browsing the archives for 23 February 2018.
Displaying 1 entry.

CMX157 displays potential to suppress replication of HIV in Stage 1 clinical trial Chimerix.

In these preclinical research, CMX157 was extremely active against all major subtypes of HIV, including strains that fail to respond to all available NRTIs. Related StoriesStudy evaluates efficiency of antiretroviral treatment in HIV-infected childrenRutgers College of Nursing takes business lead in $6 million nationwide effort to prevent new HIV infectionsNew study discovers high prevalence of HIV among pregnant refugee ladies in OntarioThe article, ‘Advancement of Hexadecyloxypropyl Tenofovir for the Treatment of Wild-Type and Nucleoside/Nucleotide-Resistant HIV’ shows up in the July 2010 problem of the journal Antimicrobial Brokers and Chemotherapy.D., the paper’s lead author and Senior Director of Virology at Chimerix.’ ‘As a promising medical stage antiretroviral with significant potential as a robust new treatment choice for HIV patients, CMX157 might trigger a new set of combination therapies,’ stated George Painter, Ph.D., Chief Scientific Chairman and Officer of the Panel of Chimerix.’..